Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Injectables, Others), By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, Others), By Region and Competition, 2020-2030F

Market Overview

Global Osteoporosis Drugs Market was valued at USD 13.40 Billion in 2024 and is expected to reach USD 16.91 Billion by 2030 with a CAGR of 4.15%. Osteoporosis is a chronic skeletal disorder characterized by reduced bone density and increased fracture risk, primarily affecting postmenopausal women and the elderly. As life expectancy increases worldwide, the incidence of osteoporosis and related fractures has surged, generating strong demand for effective pharmacological interventions.

The market comprises a wide range of drug classes, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone analogs, RANK ligand inhibitors, and calcitonin. Among these, bisphosphonates such as alendronate and risedronate have traditionally dominated due to their cost-effectiveness and long-standing clinical use. Despite the market’s positive outlook, challenges remain. The high cost of newer biologic therapies, concerns over long-term side effects, and issues related to patient compliance continue to impact market penetration.

Key Market Drivers

Growth in Healthcare Industry

The robust growth of the global healthcare industry is a key driver accelerating the expansion of the osteoporosis drugs market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Among its most lucrative and expansive segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. As healthcare systems around the world continue to evolve marked by increased investment, improved infrastructure, and broader access to medical services there is a growing emphasis on the diagnosis, prevention, and treatment of chronic age-related diseases, including osteoporosis. This shift is significantly boosting demand for pharmacological interventions that improve bone density and reduce fracture risk in vulnerable populations.

By the late 2070s, the global population aged 65 and above is expected to reach approximately 2.2 billion, exceeding the number of individuals under the age of 18. Furthermore, by the mid-2030s, the population of those aged 80 and older is projected to rise to 265 million, surpassing the number of newborns. The aging global population is a major factor contributing to this trend, and the healthcare industry is responding with tailored approaches for managing geriatric health. Osteoporosis, often referred to as a “silent disease,” remains underdiagnosed and undertreated in many regions. However, the expansion of preventive care services and routine bone mineral density (BMD) screenings is leading to earlier detection and timely treatment, thereby driving the uptake of osteoporosis drugs such as bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone analogs, and monoclonal antibodies.

Surge in Technological Advancements

The surge in technological advancements has emerged as a key driver of growth in the global osteoporosis drugs market. Innovations in drug development, delivery systems, diagnostics, and digital health platforms are transforming how osteoporosis is treated, managed, and monitored, resulting in improved patient outcomes and increased market demand. Osteoboost is the first FDA-cleared, drug-free prescription therapy developed specifically for the treatment of osteopenia in postmenopausal women. The solution is based on established scientific evidence demonstrating that precise, low-intensity mechanical stimulation can aid in maintaining and enhancing bone strength. Drawing inspiration from NASA research and validated through clinical trials, Osteoboost delivers safe and effective signals designed to support bone density.

One of the most impactful areas of progress has been in the development of next-generation therapeutics. Traditional treatments such as bisphosphonates are now being supplemented and in some cases replaced by biologics and novel anabolic agents. Drugs like monoclonal antibodies and parathyroid hormone analogs offer more targeted mechanisms of action, providing better efficacy in increasing bone mass and reducing fracture risk. These new therapies are particularly beneficial for patients who are intolerant to older treatments or who require more aggressive intervention.

Download Free Sample Report

Key Market Challenges

High Cost of Therapy

The high cost of therapy remains a significant challenge in the global osteoporosis drugs market, limiting patient access to advanced treatment options and hindering broader market growth. While the burden of osteoporosis continues to rise globally particularly among aging populations in both developed and emerging economies the affordability of long-term pharmacological treatment poses a barrier for many patients.

Innovative therapies, including biologics such as denosumab and parathyroid hormone analogs like teriparatide and abaloparatide, offer superior efficacy and improved outcomes for patients at high risk of fractures. However, these advanced medications are priced at a premium compared to older drug classes such as bisphosphonates, making them inaccessible to a large segment of the population, especially in regions with limited health insurance coverage or underdeveloped public healthcare systems.

Key Market Trends

Rise in Home-Based Osteoporosis Care

The increasing shift toward home-based osteoporosis care has emerged as a notable trend shaping the global osteoporosis drugs market. In May 2023, the International Osteoporosis Foundation (IOF) introduced the Build Better Bones platform, an innovative online resource designed to offer individuals living with osteoporosis, as well as their caregivers, practical guidance on improving bone strength and minimizing the risk of fragility fractures through targeted exercise programs and bone-supportive nutrition. A distinctive element of the platform is its dedicated section for caregivers typically close family members or friends who play a critical role in supporting elderly individuals with osteoporosis and those recovering from osteoporosis-related fractures. Driven by the growing demand for patient-centric healthcare models and the need to reduce the burden on healthcare facilities, this trend is transforming how osteoporosis is managed, particularly among elderly and mobility-restricted patients. Home-based care enables convenient, cost-effective, and continuous treatment, thereby promoting better adherence to long-term drug regimens and ultimately improving clinical outcomes.

Technological advancements have played a pivotal role in facilitating this shift. Remote monitoring tools, telemedicine platforms, and digital health apps now allow healthcare providers to assess bone health, monitor medication compliance, and adjust treatment plans without requiring frequent in-person visits. These innovations support the safe administration of osteoporosis therapies including oral medications, injectables like denosumab, and newer subcutaneous formulations within the home setting, under virtual supervision or with the assistance of home healthcare professionals.

Segmental Insights

Route of Administration Insights

Based on Route of Administration, Oral have emerged as the fastest growing segment in the Global Osteoporosis Drugs Market in 2024. This is due to its superior convenience, increased patient compliance, and ongoing innovations in oral formulations. As osteoporosis is a chronic condition that often requires long-term or lifelong treatment, the route of drug administration plays a crucial role in ensuring therapeutic success. One of the primary factors driving the growth of oral osteoporosis drugs is patient preference. Oral medications are generally easier to administer and less invasive compared to injectable or intravenous therapies, particularly among elderly populations who form the largest share of osteoporosis patients. The ability to take medication at home without medical supervision significantly improves adherence, which is critical for preventing fractures and maintaining bone density over time.

Drug Type Insights

Based on Drug Type, Parathyroid Hormone Therapy have emerged as the fastest growing segment in the Global Osteoporosis Drugs Market during the forecast period. This is due to its superior efficacy in promoting bone formation and reducing fracture risk in patients with severe or treatment-resistant osteoporosis. Unlike traditional antiresorptive therapies, such as bisphosphonates, which slow bone loss, PTH analogs like teriparatide and abaloparatide actively stimulate new bone growth by enhancing osteoblast activity. This anabolic approach offers a significant therapeutic advantage, particularly for postmenopausal women and patients with high fracture risk or glucocorticoid-induced osteoporosis.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Osteoporosis Drugs Market in 2024. This is due to a combination of demographic, clinical, and infrastructural factors. The region, particularly the United States, is characterized by a high prevalence of osteoporosis and related fractures, largely attributed to its aging population and lifestyle-related risk factors. This substantial patient pool drives consistent demand for effective pharmacological interventions, including bisphosphonates, RANK ligand inhibitors, and anabolic agents. Moreover, North America benefits from a highly developed healthcare system that facilitates early diagnosis, widespread use of bone density screening (DEXA scans), and timely therapeutic intervention.

Recent Development

• In February 2025, Sandoz, a global leader in generic and biosimilar pharmaceuticals, announced the commercial availability of WYOST and Jubbonti for patients in the United States. These products are the first and only interchangeable FDA-approved biosimilars to denosumab and are authorized for all approved indications of their respective reference biologics XGEVA and Prolia. As strategic assets within the Sandoz biosimilar portfolio, WYOST and Jubbonti play a critical role in driving growth and reinforcing the company’s commitment to establishing market leadership in the U.S. biosimilars segment.
• In September 2024, the National Institute for Health and Care Excellence (NICE) approved abaloparatide, an advanced anabolic therapy for the treatment of osteoporosis in patients at high risk of fracture in the UK. Commercially marketed under the names Tymlos, Eladynos, and Ostavaro, abaloparatide has been gaining global market momentum due to its robust clinical efficacy and increasing adoption among healthcare providers. This regulatory endorsement represents a key milestone in the UK osteoporosis landscape, introducing a novel treatment that directly targets parathyroid hormone receptors to activate osteoblasts and promote bone formation.
• In May 2025, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued positive opinions recommending the approval of marketing authorizations for three denosumab biosimilars. The approved products include Bomyntra and Conexxence by Fresenius Kabi, and Rolcya by Sandoz. Denosumab, a humanized monoclonal antibody that inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), functions by preventing the formation of osteoclasts cells responsible for bone resorption. It is indicated for the treatment of osteoporosis, therapy-induced bone loss, bone metastases, and giant cell tumour of bone.
• In January 2025, 23andMe Holding Co., a prominent human genetics company committed to empowering individuals through access to and understanding of their genetic information, launched a new polygenic risk score (PRS) report on osteoporosis exclusively for its 23andMe+ Premium members. This report assesses an individual’s genetic predisposition to developing osteoporosis, utilizing a proprietary statistical model derived from 23andMe’s extensive research database. In addition to genetic insights, the report offers personalized lifestyle recommendations aimed at mitigating risk. However, it is important to note that the report provides an estimate rather than a definitive diagnosis, as it does not capture all possible genetic variants or consider non-genetic risk factors.

Key Market Players

• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.
• Novartis International AG
• Merck & Co. Inc.
• Amgen Inc.
• Radius Health Inc.
• Actavis PLC

Report Scope

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Osteoporosis Drugs Market, By Route of Administration:

o   Oral

o   Injectables

o   Others

• Osteoporosis Drugs Market, By Drug Type:

o   Parathyroid Hormone Therapy

o   Bisphosphonates

o   Calcitonin

o   Selective Estrogen Receptor Modulators

o   Others

• Osteoporosis Drugs Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations:

Global Osteoporosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Osteoporosis Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]